Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: GlobeNewswire
• Plan to report top-line results from registration-directed SUMMIT trial in NonAdvSM patients in July 2025 • Plan to report top-line results from pivotal PEAK Phase 3 trial in 2nd-line GIST patients by end of 2025 • Plan to report top-line results from registration-directed APEX trial in AdvSM patients in 2H 2025 • Company to present at J.P. Morgan 43rd annual healthcare conference tomorrow, Tuesday, January 14 at 7:30 a.m. PT /10:30 a.m. ET WALTHAM, Mass. and BOULDER, Colo., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today highlighted the company’s key 2025 milestones ahead of its presentation at J.P. Morgan’s 43rd annual healthcare conference. “2025 will be a transformational year at Cogent Biosciences,” said Andrew Robbins, President and Chief Executive Officer. “During the year, we plan to report top-line results f
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $67.00. They now have an "overweight" rating on the stock.MarketBeat
- Cogent Biosciences: Time For A Pause [Seeking Alpha]Seeking Alpha
- Cogent Biosciences (NASDAQ:COGT) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
- Cogent Biosciences (NASDAQ:COGT) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.MarketBeat
- Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)GlobeNewswire
COGT
Sec Filings
- 12/19/25 - Form 4
- 12/19/25 - Form 4
- 12/19/25 - Form 4
- COGT's page on the SEC website